News Headlines Article

Genomic Health targets better prostate cancer treatment with new test
San Francisco Business Times

Genomic Health Inc. is hoping to do for prostate cancer what it is doing for breast cancer and colon cancer. The Redwood City company (NASDAQ: GHDX) said late Tuesday that it will sell its Oncotype DX test for prostate cancer patients, zeroing in on 17 genes that could steer some men away from surgery or radiation treatments. Genomic Health introduced Oncotype DX in 2004 for breast cancer, predicting the likelihood of chemotherapy benefitting patients as well as the chances that invasive breast cancer will recur.